Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00136214 · ClinicalTrials.gov registry record
Cerebral Effects of Pegylated Interferon in Hepatitis C Positive Subjects
A clinical trial, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- 22
- Enrollment target
NCT00136214: Completed study, sponsored by Beth Israel Deaconess Medical Center.
NCT00136214 is a clinical trial that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00136214 has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- 22 participants
- Enrollment target
Study Summary
The hypothesis of this study is that pegylated interferon would cause cognitive deficits and mood changes in hepatitis C (HCV) positive subjects.
Primary Outcome
Evaluation of changes in MR spectroscopy. reductions in ratio of Cho and MI reflect improvements in cerebral inflammation and improvement in cognition. Increases in the NAA ratio are suggestive of improvement in cognitive function.
Interventions
- DIAGNOSTIC_TEST MR brain and neuropsychiatric tests
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2004-03 |
| Est. Completion | 2008-03 |
What the finished NCT00136214 record still lists
NCT00136214 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 22 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which MR brain and neuropsychiatric tests is the first listed.
NCT00136214 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00136214 about?
NCT00136214 is a clinical study titled "Cerebral Effects of Pegylated Interferon in Hepatitis C Positive Subjects". The hypothesis of this study is that pegylated interferon would cause cognitive deficits and mood changes in hepatitis C (HCV) positive subjects.
What is the current status of trial NCT00136214?
This trial is currently completed. The enrollment target is 22 participants. The study started on 2004-03. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00136214?
The interventions under investigation include: MR brain and neuropsychiatric tests (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT00136214?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia